Proglycem
(Diazoxide)ApprovedSmall molecule
TevaProglycem is one of 106 small molecule programs targeting Injury. It is currently in Approved.
4
Indications
16
Total Trials
1
Active Trials
105
Competitors
3
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
79 competitors in Type 1 Diabetes
#DrugCompanyPhaseTrials
1Ozempic
Novo NordiskPhase 3
Proglycem
TevaApproved
Stelara
Johnson & JohnsonPhase 3
Inpefa
LLexicon Pharmaceuticals
Phase 3
Tricor
JJagotec
Phase 3
Diamox
TevaPhase 2
Kerendia
BayerPhase 2
Humira
NovartisPhase 2
Teplizumab
SanofiPhase 3
Prolia
OOrganon and Co
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Obese2 trials
Liver Transplant1 trial
The Role of Hepatic Denervation in the Dysregulation of Glucose Metabolism in Liver Transplant Recipients
Withdrawn·—·Phase 2·NCT03685773
Hypothalamic Obesity1 trial
10 more indications
Hypoglycemia1 trial
Novel Approach for the Prevention of Hypoglycemia Associated Autonomic Failure (HAAF)
Terminated·—·Phase 4·NCT03608163·4 enrolled
Type 1 Diabetes1 trial
Efficacy of Diazoxide in Type 1 Diabetes
Completed·—·Phase 4·NCT00131755·40 enrolled
Function1 trial
Unspecified1 trial
Regulatory
FDA Approval Timeline[4]
Jan 1, 1982
PROGLYCEM
NDA NDA017425
Jan 1, 1982
HYPERSTAT
NDA NDA016996
Jan 1, 1982
PROGLYCEM
NDA NDA017453
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Diazoxide. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]